Immunocore Financial Results Announcement
Immunocore Holdings plc (NASDAQ: IMCR), a pioneering biotechnology company, specializes in creating immunomodulating medications that significantly enhance the treatment outcomes for patients suffering from cancer, infections, and autoimmune disorders. The company is set to release its financial performance for the fourth quarter and the entire 2024 fiscal year on February 26, 2025.
Live Teleconference and Webcast
Alongside the financial report, Immunocore will conduct a live teleconference and webcast starting at 8:00 a.m. EST (1:00 p.m. GMT). This session will provide insights into the company’s financial results and offer updates on its business strategies and product portfolio.
How to Access the Webcast
The live call will be accessible through the 'Events' section on Immunocore’s official website, under the 'Investors' area. A replay of the event will be made available shortly after, ensuring that stakeholders and interested parties can stay informed.
Conference Call Information
For those wishing to join, the details are as follows: For domestic participants, the toll-free number is 877-405-1239, and international callers can reach +1 201-389-0851.
About Immunocore's Innovative Therapies
Immunocore is at the forefront of biomedicine, developing a unique class of therapies known as ImmTAX – Immune mobilizing monoclonal TCRs Against X diseases. These therapies target a variety of conditions, including cancers, autoimmune diseases, and infectious diseases. Utilizing its proprietary ImmTAX platform, the company is cultivating a comprehensive pipeline that addresses several therapeutic areas.
Regulatory Approvals and Product Advancement
Immunocore’s flagship oncology treatment, KIMMTRAK, has gained approval for treating adult patients with metastatic or unresectable uveal melanoma who are positive for HLA-A*02:01. The company is committed to expanding this treatment to additional patient populations through ongoing research and potential new indications.
Strategic Vision for 2025
As Immunocore approaches 2025, it remains focused on fulfilling its strategic objectives while ambitively pursuing the advancement of its clinical pipeline. This includes their intent to broaden the availability of KIMMTRAK and explore new opportunities for additional therapeutic applications.
Contact Immunocore
The public is encouraged to connect with Immunocore for further inquiries: Sébastien Desprez leads the communications team and can be reached at +44 (0) 7458030732 or via email at sebastien.desprez@immunocore.com.
For investor relations, reach out to Clayton Robertson or Morgan Warenius at +1 (215) 384-4781 or by emailing ir@immunocore.com.
Frequently Asked Questions
What financial results will Immunocore release?
Immunocore will disclose its financial outcomes for the fourth quarter and the full year ended December 31, 2024.
When is the financial call scheduled?
The financial call is scheduled for February 26, 2025, at 8:00 a.m. EST.
How can I access the live teleconference?
The teleconference can be accessed through the 'Events' section on the Immunocore website.
Who can I contact for more information?
For inquiries, you can contact Sébastien Desprez at Immunocore.
What is KIMMTRAK?
KIMMTRAK is an innovative therapy developed by Immunocore aimed at treating specific types of cancer, particularly metastatic uveal melanoma.
